Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination

ABSTRACT Worldwide, the Mycobacterium bovis BCG vaccine is one of the most widely used vaccines. However, it appears to be ineffective in preventing pulmonary tuberculosis. Here, we show that pulmonary BCG vaccination of mice with a broad dose range provides superior protection against Mycobacterium tuberculosis challenge compared to that of subcutaneous vaccination.

[1]  S. Lockhart,et al.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.

[2]  I. Knezevic,et al.  WHO Informal Consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22-23 September 2009. , 2010, Vaccine.

[3]  R. Andrews.  Vaccines: A Biography , 2010 .

[4]  P. Upadhyay,et al.  Immunogenicity and Protective Efficacy of “Mycobacterium w” against Mycobacterium tuberculosis in Mice Immunized with Live versus Heat-Killed M. w by the Aerosol or Parenteral Route , 2008, Infection and Immunity.

[5]  A. Pawłowski,et al.  Should a new tuberculosis vaccine be administered intranasally? , 2007, Tuberculosis.

[6]  V. Mischenko,et al.  CD27low CD4 T Lymphocytes That Accumulate in the Mouse Lungs during Mycobacterial Infection Differentiate from CD27high Precursors In Situ, Produce IFN-γ, and Protect the Host against Tuberculosis Infection1 , 2007, The Journal of Immunology.

[7]  P. Andersen,et al.  The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.

[8]  G. Källenius,et al.  Recent developments in tuberculosis vaccines , 2005, Current opinion in infectious diseases.

[9]  P. Marsh,et al.  Intranasal bacille Calmette–Guérin (BCG) vaccine dosage needs balancing between protection and lung pathology , 2004, Clinical and experimental immunology.

[10]  A. Apt,et al.  CD4 T cells producing IFN‐γ in the lungs of mice challenged with mycobacteria express a CD27‐negative phenotype , 2004, Clinical and experimental immunology.

[11]  W. Bishai,et al.  Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG , 2004, Infection and Immunity.

[12]  Z. Xing,et al.  Single Intranasal Mucosal Mycobacterium bovis BCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis , 2004, Infection and Immunity.

[13]  H. McShane,et al.  Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .

[14]  I. Orme,et al.  Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis. , 2002, Tuberculosis.

[15]  A. Bean,et al.  Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of Prior Mycobacterium bovis BCG Immunization , 2002, Infection and Immunity.

[16]  Jun Wang,et al.  Genetically Determined Disparate Innate and Adaptive Cell-Mediated Immune Responses to Pulmonary Mycobacterium bovis BCG Infection in C57BL/6 and BALB/c Mice , 2000, Infection and Immunity.

[17]  D. Smith,et al.  BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. , 1993, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  C. Meyer,et al.  Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study , 1975, Cancer.

[19]  S. Rosenthal,et al.  Aerogenic BCG vaccination against tuberculosis in animal and human subjects. , 1968, The Journal of asthma research.